Sotera Health Company announced its financial results for the first quarter ended March 31, 2025, with net revenues increasing 2.6% to $255 million, or 4.4% on a constant currency basis, compared to Q1 2024. The company reported a net loss of $13 million, or $0.05 per diluted share, which includes a $31 million settlement related to ethylene oxide (EO) claims against Sterigenics.
Adjusted EBITDA for the first quarter of 2025 increased by 8.8% to $122 million, or 11.2% on a constant currency basis. Adjusted Earnings Per Diluted Share (Adjusted EPS) was $0.14, an increase of $0.01 compared to the first quarter of 2024. The company reaffirmed its 2025 outlook, with updates to foreign currency assumptions.
On April 30, 2025, Sotera Health closed on an amendment to its revolving credit facility, increasing its size by $176 million to a total of $600 million and extending its maturity date to April 2030. This amendment enhances the company's liquidity, which stood at $304 million in cash and cash equivalents as of March 31, 2025. The net leverage ratio improved to 3.6x from 3.7x at year-end 2024.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.